MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2020.10.010

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2020

Successful toxicity reduction during delayed intensification in the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 study.

Oh Bernice L Z, Lee Shawn H R, Foo Koon M, Chiew Kean H, Seeto Zelia Z L, Chen Zhi W, Neoh Cheryl C C, Liew Germaine S M, Eng Jing J, Lam Joyce C M, Chan Yiong H, Quah Thuan C, Tan Ah M, Yeoh Allen E J

Историческая статьяСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

UNLABELLED: In non-high-risk (non-HR) patients, the Malaysia-Singapore Acute Lymphoblastic Leukaemia 2003 (MS2003) study achieved good outcomes. However, its delayed-intensification (DI) phase, comprising repeated blocks of protocol III (2003-PIII), was toxic and caused significant treatment delays. The successor MS2010 study attempted to lower DI toxicity by replacing myelosuppressive drugs (doxorubicin, cytarabine) with vincristine and asparaginase.

PATIENTS AND

METHODS

We analysed 1748 admissions for fever in 315 Singapore children with non-HR acute lymphoblastic leukaemia (ALL) (MS2003, n = 183; MS2010, n = 132), comprising 76% of the total cohort (n = 413), to study the impact of these changes.

RESULTS

The new 2010-PVa which has no doxorubicin, was associated with significantly fewer hospitalisations due to fever (0.08 versus 0.30 admissions per block [A/blk], p < 0.001), as than 2003-PIIIa. Similarly in 2010-PIIIb and PVb, where one block of cytarabine was replaced by two doses of vincristine, admissions for fever were also fewer (0.47 versus 0.74 A/blk, p < 0.001) than in 2003-PIIIb. However, the addition of single doses of vincristine and asparaginase in 2010-PIIIa, even with a mandatory seven-day rest, led to more hospitalisations (0.45 A/blk, p < 0.001), increased risk of bacteraemia (relative-risk (RR) = 7.66, p = 0.005) and critical-care admissions (RR = 4.31, p = 0.13). Despite this, overall treatment-related mortality decreased from 2.7% to 0.8%. Taken together, the reduced phase delays allowed earlier completion of the intensive phase of treatment (standard risk: 38.1 versus 49.4 weeks, p < 0.001; intermediate risk: 50.9 versus 58.8 weeks, p < 0.001), while maintaining excellent 10-year event-free survival of 95.4% and overall survival of 96.2%.

CONCLUSIONS

In non-HR ALL, replacing doxorubicin/cytarabine with vincristine/asparaginase during some DI blocks is effective in reducing toxicity without compromising outcomes.

CLINICAL TRIAL INFORMATION: NCT0289464.

Для цитирования: Oh Bernice L Z, Lee Shawn H R, Foo Koon M, Chiew Kean H, Seeto Zelia Z L, Chen Zhi W, Neoh Cheryl C C, Liew Germaine S M, Eng Jing J, Lam Joyce C M, Chan Yiong H, Quah Thuan C, Tan Ah M, Yeoh Allen E J. Successful toxicity reduction during delayed intensification in the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 study.. European journal of cancer (Oxford, England : 1990). 2020. DOI: 10.1016/j.ejca.2020.10.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.